Ro's Reitano: Make the Patient the Customer of US Healthcare
Key points
Key takeaways from an Invest Like the Best interview with Ro co-founder and CEO Zachariah Reitano (November 2026):
The patient is not the customer. Reitano argues the central flaw of US healthcare is that whoever controls the flow of money at the point of purchase is the customer, and patients — paying through insurance, taxes and suppressed wages — are not. Where patients are the customer, cash-pay markets such as LASIK and cosmetic surgery see prices fall and quality rise.
Healthcare's share of GDP should be higher, not lower. He expects US healthcare to keep growing towards 50–70% of GDP within 10–15 years, framed through Jevons' paradox: the market expands as the unit cost of health falls, and a healthy year is the one good with no diminishing marginal returns.
Praise for acute care, not the bill. The US system is "fantastic" at acute care — higher cancer survival and cardiac and stroke outcomes than most OECD peers — while life-expectancy stagnation reflects the "fast clock" of gun deaths, accidents and overdoses plus the "slow clock" of rising chronic disease.
GLP-1s as the foil for the whole system. Politicians tried for 25 years to get transparent list prices; pharma going direct-to-consumer eliminates the list-to-net gap, with GLP-1 cash prices dropping from roughly $1,300 to $149 by bypassing PBMs and insurers. He calls PBMs "the appendix of the healthcare system", replaced by software.
Ro's scale-up. Ro is the leading US provider of GLP-1s across cardiometabolic health, sexual health, dermatology and fertility, growing from a ~$250M to a $3B+ run rate in four years with fewer employees than in 2021, built on an EMR, CLIA lab, pharmacy software and provider network it built itself.
GLP-1s treat the leading causes of death. Indications now span diabetes, obesity, heart disease, sleep apnoea and liver and kidney disease, with research under way in nerve degeneration, pain, addiction, mental health and cancer prevention — "the slow clock".
Continued innovation is the only moat. Ro helps patients check insurance for free (over 1% of the US population), offers cash-pay and pharma multi-month subscriptions that save patients $600–$1,800 a year, and framed itself as a demand aggregator in the Ben Thompson sense.
Read more: Invest Like the Best
